Neither a higher proportion of EZH2-expressing tumor cells (defined as exceeding the group median of 40%) nor intratumoral p53 expression were identified as significant predictors of an unfavorable outcome among young HNSCC patients (although the trend of the HR was coherent with the known biological nature of both mediators). This evidence concerns the gene EZH2 and neoplasm.